Dr. Cesare Patrone

Karolinska Institute, Sweden

Email: [email protected]

Qualifications

1998  Ph.D., Biotechnologies appli. to Pharmacology, Dept. of Pharmacological Sciences, Italy

Publications (Selected)

1. Augestad, I. L., Dekens, D., Karampatsi, D., et al. (2022). Normalisation of glucose metabolism by exendin-4 in the chronic phase after stroke promotes functional recovery in male diabetic mice. British Journal of Pharmacology, 179(4), 677–694.
2. Augestad, I. L., Pintana, H., Larsson, M., et al. (2020). Regulation of glycemia in the recovery phase after stroke counteracts the detrimental effect of obesity-induced type 2 diabetes on neurological recovery. Diabetes, 69(9), 1961–1973.
3. Chiazza, F., Pintana, H., Lietzau, G., et al. (2021). The stroke-induced increase of somatostatin-expressing neurons is inhibited by diabetes: A potential mechanism at the basis of impaired stroke recovery. Cellular and Molecular Neurobiology, 41(3), 591–603.
4. Darsalia, V., Vercalsteren, E., Karampatsi, D., et al. (2024). The need for registry-based studies in diabetes and stroke: A unique opportunity to understand whether diabetic treatments improve post-stroke outcome. Diabetes Obesity & Metabolism, 26(7), 2527–2530.
5. Darsalia, V., Vercalsteren, E., Karampatsi, D., et al. (2025). The normalisation of insulin resistance before stroke improves functional outcome in type 2 diabetes. Diabetologia, 68(Suppl 1), S24.
6. Elabi, O. F., Karampatsi, D., Vercalsteren, E., et al. (2023). DPP-4 inhibitor and sulfonylurea differentially reverse type 2 diabetes-induced blood-brain barrier leakage and normalize capillary pericyte coverage. Diabetes, 72(3), 405–414.
7. Hammarlund, M. E., Darsalia, V., Mjörnstedt, F., et al. (2021). The selective alpha7 nicotinic acetylcholine receptor agonist AR-R17779 does not affect ischemia-reperfusion brain injury in mice. Bioscience Reports, 41(6), Article BSR20210736.
8. Karampatsi, D., Zabala, A., Wilhelmsson, U., et al. (2021). Diet-induced weight loss in obese/diabetic mice normalizes glucose metabolism and promotes functional recovery after stroke. Cardiovascular Diabetology, 20(1), Article 240.
9. Lietzau, G., Magni, G., Kehr, J., et al. (2020). Dipeptidyl peptidase-4 inhibitors and sulfonylureas prevent the progressive impairment of the nigrostriatal dopaminergic system induced by diabetes during aging. Neurobiology of Aging, 89, 12–23.
10. Lietzau, G., Ntika, S., Pintana, H., et al. (2022). A high-fat diet increases activation of the glucagon-like peptide-1-producing neurons in the nucleus tractus solitarii: An effect that is partially reversed by drugs normalizing glycemia. Cellular and Molecular Neurobiology, 42(6), 1995–2002.
11. Lietzau, G., Nyström, T., Wang, Z. D., et al. (2020). Western diet accelerates the impairment of odor-related learning and olfactory memory in the mouse. ACS Chemical Neuroscience, 11(21), 3590–3602.
12. Vercalsteren, E., Karampatsi, D., Buizza, C., et al. (2024). The SGLT2 inhibitor empagliflozin promotes post-stroke functional recovery in diabetic mice. Cardiovascular Diabetology, 23(1), Article 88.
13. Vercalsteren, E., Karampatsi, D., Buizza, C., et al. (2025). Prevention of metabolic impairment by dietary nitrate in overweight male mice improves stroke outcome. Nutrients, 17(15), Article 2434.
14. Vercalsteren, E., Karampatsi, D., Dekens, D., et al. (2023). The pre-stroke induction and normalization of insulin resistance respectively worsens and improves functional recovery. International Journal of Molecular Sciences, 24(4), Article 3989.
15. Vercalsteren, E., Karampatsi, D., Neicu, M., et al. (2026). Normalization of insulin resistance rather than hyperglycemia before stroke improves functional outcomes in a mouse model of type 2 diabetes. Diabetes, 75(5), 852–859.
16. Vercalsteren, E., Karampatsi, D., Neicu, M., et al. (2026). Pre-stroke weight loss by glucagon-like peptide 1 receptor and neuropeptide Y receptor Y2 activation improves post-stroke functional recovery in male diabetic mouse models. Diabetologia, 69(1), 230–243.
17. Vercalsteren, E., Klein, T., Patrone, C., et al. (2026). Survodutide improves stroke outcome in obese/type 2 diabetic mice. Diabetes, 75(Suppl 1), Article 2551P.
18. Vercalsteren, E., Mazya, M. V., Nyström, T., et al. (2026). The need for clinical studies assessing whether weight loss improves functional outcome after stroke in diabetes. BMC Medicine, 24(1), Article 215.
19. Vieira, J. P. P., Karampatsi, D., Vercalsteren, E., et al. (2024). Nuclear magnetic resonance spectroscopy reveals biomarkers of stroke recovery in a mouse model of obesity-associated type 2 diabetes. Bioscience Reports, 44(7), Article BSR20240249.
20. Zabala, A., Darsalia, V., Holzmann, M. J., et al. (2020). Risk of first stroke in people with type 2 diabetes and its relation to glycaemic control: A nationwide observational study. Diabetes Obesity & Metabolism, 22(2), 182–190.

Profile Details
https://ki.se/en/people/cesare-patrone
https://www.researchgate.net/profile/Cesare-Patrone
https://www.sciencedirect.com/author/6603353795/cesare-p-patrone

WOS ResearcherID: AFV-5415-2022